argenex SE $ARGX Shares Bought by Candriam S.C.A.

Candriam S.C.A. raised its stake in argenex SE (NASDAQ:ARGX) by 5.8% during the third quarter, Holdings Channel reports. The firm owned 48,200 shares of the company’s stock after purchasing an additional 2,633 shares during the period. Candriam S.C.A.’s holdings in argenex were worth $35,550,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. New York Life Investment Management LLC increased its holdings in argenex by 3.4% in the 3rd quarter. New York Life Investment Management LLC now owns 1,075 shares of the company’s stock valued at $793,000 after purchasing an additional 35 shares in the last quarter. Roman Butler Fullerton & Co. purchased a new stake in argenex during the 3rd quarter worth approximately $273,000. Smartleaf Asset Management LLC raised its position in shares of argenex by 48.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 382 shares of the company’s stock valued at $275,000 after purchasing an additional 125 shares in the last quarter. Portside Wealth Group LLC grew its position in shares of argenex by 2.8% during the third quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock worth $430,000 after buying an additional 16 shares in the last quarter. Finally, Bessemer Group Inc. grew its position in shares of argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after buying an additional 47 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on ARGX. Wedbush reiterated an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Wednesday, January 14th. JPMorgan Chase & Co. boosted their target price on shares of argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Stifel Nicolaus increased their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Royal Bank Of Canada lifted their price target on argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, Wolfe Research restated a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Trading Up 2.1%

Shares of argenex stock opened at $828.24 on Tuesday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The stock has a market capitalization of $51.25 billion, a price-to-earnings ratio of 35.56, a PEG ratio of 0.70 and a beta of 0.37. The business’s 50 day simple moving average is $842.75 and its 200-day simple moving average is $795.35.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.